Market Overview

UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership

Share:
Related LGND
35 Biggest Movers From Yesterday
Mid-Afternoon Market Update: Dow Gains 90 Points; Micronet Enertec Technologies Shares Drop
Midday Gainers / Losers (Seeking Alpha)

In a report published Monday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $23.00 to $26.00.

In the report, Rivkind noted, “On March 14 the company announced its license and global supply agreement with Spectrum Pharmaceuticals on Captisol-enabled Melphalan for the treatment of multiple myeloma. Ligand received a $3M upfront payment and negotiated a healthy double-digit royalty (we estimate 20%) in addition to $50M in milestones that will be based on multiple regulatory and commercial events such as NDA acceptance, FDA approval, and launch. Spectrum is also taking over development costs, effective immediately.”

Ligand Pharmaceuticals closed on Friday at $23.27.

Latest Ratings for LGND

DateFirmActionFromTo
Nov 2017Deutsche BankDowngradesHoldSell
Nov 2017H.C. WainwrightMaintainsBuy
Sep 2017H.C. WainwrightAssumesBuy

View More Analyst Ratings for LGND
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings

 

Related Articles (LGND)

View Comments and Join the Discussion!

Partner Center